Is it time to test metformin in breast cancer prevention trials? A reply to the authors

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 9, 2009, Pages 2565-

  Barba, Maddalena ^a   Muti, Paola ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PLACEBO;

BREAST CANCER; CANCER PREVENTION; HUMAN; HYPOXEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 70349330318     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0515     Document Type: Letter

References (5)

1. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Cancer Epidemiol Biomarkers Prev 2009;18:701-704
2. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-579
3. Salpenter S, Greyber E, Pasternak G, Salpenter E. Riskof fatal and non fatal lactic acidosis with metformin in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006:CD002967.
4. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003;326:4-5.
5. Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician 2009;79:29-36.